jump to content jump to footer

Categories:

A look ahead with mint Lesion 3.3
Mint Medical is pleased to announce the recent release of their software product version 3.3 of mint Lesion™ which was completed during recent weeks.…
New iRECIST Oncologic Response Criteria already in clinical use at the University Medical Center – Tübingen, Germany
Shortly following the release of the new iRECIST- oncologic response criteria (Lancet Oncology, March 2017) the University Medical Center in Tübingen,…
Mrs. Kelie Luby joins Mint Medical's team
Mrs. Kelie Luby will join Mint Medical’s team from January 2017 as new Vice President Clinical Trials Software and will be introduced at the upcoming…
Novel oncologic therapy response criteria (iRECIST and more)
Advances in oncology therapies, such as novel immune-related agents, require adapted and refined criteria and guidelines for the assessment and…
Customized templates in mint Lesion 3.3
mint Lesion™ 3.3 features a novel data and knowledge modelling core that enables you to customize read procedures and reporting templates – or design…
Data Analytics and Instant-Trial Research
Context-driven read procedures in mint Lesion™ facilitate the generation of well-structured data on a large scale. At RSNA 2016, Mint Medical presents…
Leipzig shines as new host for German Radiology Congress
4 days full of sun – there couldn’t be any better circumstances for Leipzig to present itself as new host of the German Radiology Congress. Mint…
ECR 2016 in Vienna – Structured Reporting awakens
The ECR 2016 in Vienna achieved a new record in number of participants: 25.998 people visited the congress. Mint Medical also realized a personal best…
Season opening at IROS in Salzburg
IROS 2016, the meeting of the German, Austrian and Swiss Societies for Interventional Radiology in Salzburg from January 14th - 16th, was our season…